Last reviewed · How we verify
Part 2: Treatment C, moxifloxacin
At a glance
| Generic name | Part 2: Treatment C, moxifloxacin |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants (PHASE1)
- Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants (PHASE1)
- An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics (PHASE1)
- A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects (PHASE1)
- Electrophysiological Effects of Potential QT Prolonging Drugs (PHASE1)
- Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat (PHASE1)
- A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function (PHASE1)
- Study of the Effects of Intravenous Exenatide on Cardiac Repolarization (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part 2: Treatment C, moxifloxacin CI brief — competitive landscape report
- Part 2: Treatment C, moxifloxacin updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI